Repligen appoints Dr. Konstantin Konstantinov to board; all directors re-elected at annual meeting

REPLIGEN CORP

Konstantinov elected to board effective May 26, 2022; brings 30 years of bioprocessing expertise from Genzyme and Bayer.
Annual meeting results: all six director nominees elected with >94% support; Ernst & Young ratified as auditor; say-on-pay approved.
Severance and change in control plan amended to adjust treatment of performance-based equity awards upon change in control.
CEO Tony Hunt's employment agreement amended to align equity treatment with the amended severance plan.
Director compensation policy amended for new non-employee director equity grants; new director granted initial option worth $170,000.

item 5.02 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Konstantin Konstantinov

Director

RGEN · REPLIGEN CORP

Effective: 2022-05-26
Filed: June 1, 2022, 7:59 PM ET

the Board elected Konstantin Konstantinov, Ph.D. to the Board, effective May 26, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Konstantin Konstantinov was elected as Director at REPLIGEN CORP.

Action: elected
Role: Director

Exact text from the filing

the Board elected Konstantin Konstantinov, Ph.D. to the Board, effective May 26, 2022

View on SEC.gov

REPLIGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-22-165344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.